US con­sid­ers use of ex­pired mon­key­pox vac­cines amid ris­ing de­mand for dos­es

As the US looks to stretch its stock­pile of Bavar­i­an Nordic’s mon­key­pox vac­cine, reg­u­la­tors are work­ing with the com­pa­ny to as­sess whether some ex­pired dos­es can still be used.

Bavar­i­an Nordic CEO Paul Chap­lin told Reuters on Wednes­day that about half a mil­lion ex­pired dos­es in the US’ na­tion­al stock­pile may still be vi­able, though it would be up to reg­u­la­tors to make the fi­nal call.

An FDA spokesper­son con­firmed to End­points News that it is “ac­tive­ly work­ing with Bavar­i­an Nordic and AS­PR/BAR­DA to ob­tain the nec­es­sary in­for­ma­tion to po­ten­tial­ly re­qual­i­fy a sub­set of ex­pired dos­es that meet cer­tain qual­i­ty spec­i­fi­ca­tions.” The New York Times re­cent­ly re­port­ed that about 20 mil­lion dos­es of the vac­cine have ex­pired in the US na­tion­al stock­pile.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER